findmyKOL

Michael Rogawski, MD

Enriched profile

Distinguished Professor, Department of Neurology (joint appointment in Pharmacology) · University of California, Davis

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Sacramento, CA · West · United StatesSpecialtyNeurologyFocusEpilepsy
Active KOLfindmyKOL type: NationalLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2010–2026

Michael Rogawski is Distinguished Professor, Department of Neurology (joint appointment in Pharmacology) at University of California, Davis. OpenAlex indexes 373 publications with 26,253 citations (h-index 89); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 13 Oct 2026

Michael Rogawski, MD, is Distinguished Professor, Department of Neurology (joint appointment in Pharmacology) at University of California, Davis. The public record shows 373 publications with 26,253 citations (h-index 89), centered on Epilepsy. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 9 companies, 8 NIH-funded awards (2010–2026).

  • Most recent indexed publication: 2025 · Epilepsia
  • Top research focus: Epilepsy
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Epilepsy2 trialsWounds and Injuries1 trialBrain Injuries, Traumatic1 trial

Research focus

OpenAlex concept fingerprint
Epilepsy

Drugs & molecules

across trials, industry payments and publications
Ztalmygeneric · GanaxoloneClinical trials—Industry payments5Publications1Valtocogeneric · DiazepamClinical trials—Industry payments1Publications3FYCOMPAgeneric · PerampanelClinical trials—Industry payments1Publications2Xcoprigeneric · CenobamateClinical trials—Industry payments5Publications—Epidiolexgeneric · CannabidiolClinical trials—Industry payments1Publications—Finteplageneric · FenfluramineClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Marinus Pharmaceuticals, Inc.Clinical trials—Industry payments7Merck Sharp & Dohme LLCClinical trials—Industry payments7SK Life Science, Inc.Clinical trials—Industry payments7Jazz Pharmaceuticals Inc.Clinical trials—Industry payments2Aadi Bioscience, Inc.Clinical trials—Industry payments1Eisai Inc.Clinical trials—Industry payments1Michael A. Rogawski, MD, PhDClinical trials1Industry payments—Neurelis, Inc.Clinical trials—Industry payments1Ucb SaClinical trials—Industry payments1UCB, Inc.Clinical trials—Industry payments1University of California, DavisClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
373publications

Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.

26,253citations

Total citations across indexed works.

89h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
8NIH grants · 2010–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Oct 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    91.1%
    Calcitonin Gene-related Peptide Receptor Antagonist27.1%
    Nurtec Odt68%Qulipta32%
    Part D<11 patients
    Serotonin-1b and Serotonin-1d Receptor Agonist18.7%
    Sumatriptan Succinate68%Frovatriptan Succinate32%
    Part D<11 patients

    + 4 more classes in this area

  • Musculoskeletal

    5.8%
    Cyclooxygenase Inhibitor5.8%
    Ketorolac Tromethamine100%
    Part D<11 patients
  • Cardiovascular

    3.2%
    Angiotensin receptor blocker (ARB)3.2%
    Candesartan Cilexetil100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

8 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/michael-rogawski-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Google Scholar

    scholar.google.com/citations

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/2051788143_Michael_A_Rogawski

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • LinkedIn

    linkedin.com/in/michael-rogawski-4aa0673

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Other

    curegabaa.org/event/cure-gaba-a-understanding-gaba-a-and-its-relationship-to-epilepsy

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curegabaa.org ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Past president

    American Society for Experimental Neurotherapeutics

    2014
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mr.ucdavis.edu ↗
  • Former Chair

    UC Davis Department of Neurology

    2012
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mr.ucdavis.edu ↗
  • Former Senior Investigator and Chief

    Epilepsy Research Section, NINDS/NIH

    2006
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mr.ucdavis.edu ↗
  • Founder and co-chief editor

    Epilepsy Currents (journal)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mr.ucdavis.edu ↗
  • Board member

    American Epilepsy Society

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mr.ucdavis.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.